Acute Respiratory Distress Syndrome Pipeline Therapeutics Development Review H2 2015

Press Release   •   Dec 11, 2015 08:49 EST

This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Complete report on H2, 2015 Pipeline Review of “Acute Respiratory Distress Syndrome” addition with 30 market data tables and 14 figures, spread across 91 pages is .

This report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from our proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by our professional's team. Drug profiles/records featured in the report undergoes periodic updating following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Companies Discussed/Mentioned in this Research:

Altor BioScience Corporation, Athersys, Inc., BioMarck Pharmaceuticals, Ltd., Faron Pharmaceuticals Oy, FirstString Research, Inc., GlaxoSmithKline Plc, Histocell S.L., Myelo Therapeutics GmbH, Phylogica Limited, Serendex Pharmaceuticals A/S, Silence Therapeutics Plc and Therabron Therapeutics, Inc.

Drugs Profile Discussed in this Research:

ALT-836, BIO-10901, CG-367, Cyndacel-M, GSK-2586881, GSK-2862277, interferon beta-1a, molgramostim, Monoclonal Antibodies to Inhibit uPA for Infectious Disease and Respiratory Disorders, MultiStem, Myelo-001, Oligonucleotide to Inhibit Endothelin-1 for Pulmonary Arterial Hypertension, PYC-35, PYC-36, PYC-38, PYC-98, Recombinant Proteins for Acute Lung Injury and Acute Respiratory Distress Syndrome, S-1229, SAN-101, Small Molecule to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders, Stem Cell Therapy for Inflammatory Lung Diseases, Stromal Cell Therapy for Acute Respiratory Distress Syndrome and Synthetic Peptide for Acute Lung Injury and Acute Respiratory Distress Syndrome

Inquire before buying for this report . (This is a premium report price at US$2000 for a single user PDF license)


  • The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy:

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Acute Respiratory Distress Syndrome
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Acute Respiratory Distress Syndrome pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Explore More Research Report on Respiratory Therapeutics Market.

In the era of air pollution, it is very tough to keep your lungs free from any damages. Minor or major, intentionally or non-intentionally, each of them has a solution to be referred. But that is the main role of the Respiratory therapists. Apart from this aspect, let us discuss on the marketing strategies used in the world of Respiratory therapeutics.

Since few decades, the market of over-the-counter (OTC) respiratory drugs has been on a hike. With instant yet temporary solutions, this Respiratory therapeutics is in great demand. These genuinely increases the productivity and make pharmaceuticals go much cheaper. Even the prescription pharmaceuticals are no less to compete with the OTC market. The reason is patients have become cautious about the intricacies that get involved on self-prescription from the nearby retail drug store. is an online database of market research reports offer in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries